[Federal Register Volume 62, Number 248 (Monday, December 29, 1997)]
[Notices]
[Pages 67644-67645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-33746]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Cooperative Research and Development Agreement (CRADA) 
Opportunity and/or Licensing Opportunity for Materials and Methods for 
Protection of Tissue From Ischemic Damage

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health is seeking CRADA partners 
and/or licensees for the further development, evaluation, and 
commercialization of materials and methods for protecting tissues from 
cell injury by Ischemia. The invention claimed in U.S. Patent 
Application Serial No. 60/053,843, ``12(S)=HpETE (A 12=Lipoxygenase 
Metabolite) Significantly Reduces Cell Injury,'' is available for 
licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or 
further development under one or more CRADAs in several clinically 
important applications as described below in the Supplementary 
Information.

DATES: CRADA proposals should be received on or before March 30, 1998 
for priority consideration. However, CRADA proposals submitted 
thereafter will be considered until a suitable CRADA Collaborator is 
selected.

ADDRESSES: CRADA proposals and questions should be addressed to Dr. 
Jonathan Gottlieb, National Heart, Lung, and Blood Institute, 
Technology Transfer Service Center, 31 Center Drive MSC 2490, Room 
1B32, Bethesda, Maryland 20892-2490; Telephone: 301/402-5579; Fax: 301/
594-3080; E-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="387f574c4c54515d72785f4f5f594c5d165650545a5116565150165f574e16">[email protected]</a>

    Questions about the licensing opportunity should be addressed to 
Carol Lavrich, Technology Licensing Specialist, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, Maryland 20852-3804; Telephone 301/496-7735 ext. 
287; Fax 301/402-0220; E-mail: Carol--L<a href="/cdn-cgi/l/email-protection#aacbdcd8c3c9c2eac4c3c284cdc5dc"><span class="__cf_email__" data-cfemail="a9c8dfdbc0cac1e9c7c0c187cec6df">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Ischemia and reperfusion injury are 
significant causes of tissue damage in diseases and conditions such as 
heart attack, stroke and in organ transplantation. Recently, scientists 
at the National Institute of Environmental Health Sciences and Duke 
University, while investigating the phenomena of preconditioning, 
discovered and developed a highly effective method for protecting 
tissues from cell injury by ischemia by use of 12(S)=HpETE.
    Previously developed treatments to prevent ischemic damage are 
greatly limited in their effectiveness. TPA, routinely used to dissolve 
blood clots, thereby allowing greater blood flow, does not prevent 
ischemic tissue injury. Aspirin has been shown to have only a small 
protective effect in the cardiovascular system. However, the above new 
method demonstrates a dramatic protective effect--up to 82% recovery in 
initial studies--when administered during injury, as seen in animal 
models. The protective effect of 12(S)-HpETE was discovered during 
investigation of the 12-lipoxygenase-related protective effect of 
ischemic preconditioning and, unlike other agents, 12(S)-HpETE has no 
known undesirable side effects.
    Uses of such an invention may include treatment of tissue during 
angioplasty and treatment of organs intended for transplantation to 
limit the chance of damage.
    This research was published in Circulation Research 76: 457-467, 
1995.
    Information about the patent application and pertinent information 
not yet publicly described can be obtained under a Confidential

[[Page 67645]]

Disclosure Agreement. Respondees interested in licensing the 
invention(s) will be required to submit an Application for License to 
Public Health Service Inventions. Respondees interested in submitting a 
CRADA proposal should be aware that it may be necessary to secure a 
license to the above patent rights in order to commercialize products 
arising from a CRADA.

    Dated: December 16, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-33746 Filed 12-24-97; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>